A double-blinded extension study to provide adjuvant treatment with single agent Herceptin�® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03
A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin�® in subjects with HER2 positive early breast cancer
100 项与 Tanvex Biologics, Inc. 相关的临床结果
0 项与 Tanvex Biologics, Inc. 相关的专利（医药）
100 项与 Tanvex Biologics, Inc. 相关的药物交易
100 项与 Tanvex Biologics, Inc. 相关的转化医学
